Medigene AG / Medigene's Drug Veregen® Launched in Canada . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Press release
Martinsried/Munich, July 17, 2014. Medigene AG (http://www.medigene.de) (MDG1, Frankfurt, Prime Standard) announces the launch of its drug Veregen® (http://www.medigene.de/veregen) (Sinecatechins Ointment, 10%) for the treatment of genital warts in Canada through the marketing partner Paladin Labs Inc. (who acquired Triton Pharma). Within the scope of the license agreement, Medigene receives sales milestone payments as well as royalties on Veregen® sales.
Up to now, Veregen® is available in the USA, in 15 European countries (Germany, Austria, Switzerland, Spain, Serbia, the Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Czech Republic, Slovakia, Hungary, and Poland), and in Taiwan. The drug has obtained market approval in a number of additional countries. Several marketing partnership agreements have been concluded in Europe, Asia, and America.
About Veregen®: Veregen®, a topical treatment for external genital or perianal warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. Sinecatechins 10% & 15% Ointment (Veregen®) has been included in the 2012 European Guideline for the Management of Anogenital Warts. In addition, in its current Sexually Transmitted Diseases Treatment Guidelines, the US Centers for Disease Control and Prevention includes Sinecatechins 15% Ointment (Veregen®) as a possible option for treating genital warts.
About Paladin Labs Inc.: Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for Canadian and select emerging markets. Paladin has a focused marketing and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies. Paladin is an operating company of Endo International plc, a global specialty healthcare company focused on improving patients' lives while creating shareholder value. Learn more at www.endo.com (http://www.endo.com).
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partners. Medigene has various drug candidates in clinical development and it is developing highly innovative treatment platforms. For more information, please visit www.medigene.de (http://www.medigene.de/).
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.
Contact
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com (mailto:investor@medigene.com)
To unsubscribe from the press release distribution list, please go to: www.medigene.de/unsubscribe (http://www.medigene.de/unsubscribe)
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire
--- End of Message ---
Medigene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
